Christy Wong is a corporate lawyer based in Hong Kong. She has extensive commercial and corporate finance experience, with a particular focus on initial public offerings, mergers and acquisitions, and regulatory and compliance matters for listed companies.
Representative experience
IPO / Listing
- Breton Technology (1333.HK): H-share Main Board IPO and global offering. Represented CICC and CMB International.
- Shandong Boan Biotechnology (6955.HK): H-share spin-off listing. Represented UBS and Essence International, now known as SDICSI.
- Butong Group (6090.HK): Main Board IPO and global offering. Represented CITIC Securities and Haitong.
- Hanx Biopharmaceuticals (Wuhan) (3378.HK): H-share Main Board listing under Chapter 18A of the Listing Rules and global offering. Represented ICBC International.
- Tage iDriver: proposed H-share Main Board listing. A1 application filed. Represented Huatai International.
Annual Retainer
- China Qidian Guofeng (1280.HK)
- Inkeverse (3700.HK)
- Mobvista (1860.HK)
- NagaCorp (3918.HK)
- Zhejiang Expressway (0576.HK)
Other Relevant Experence
- China Dongxiang (3818.HK): Off-market buy-back of 256,090,025 shares, representing approximately 4.34% of the company’s total issued share capital. The buy-back formed part of a comprehensive settlement arrangement between the company and certain current and former members of management in connection with its previous share incentive schemes.
- China Qidian Guofeng (1280.HK): Loan capitalization involving issuance of HK$185.50 million shares under specific mandate and application for a whitewash waiver.
Admissions
- qualified in Hong Kong
Languages
- English
- Cantonese
- Mandarin Chinese